AML (Acute Myeloid Leukemia) Clinical Trials: FLT3, IDH, NPM1, and New vs Relapsed
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Its clinical trials are distinct from those for acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). For an AML trial search, the key details include whether the disease is newly diagnosed, relapsed or refractory, the mutation results, and whether intensive treatment is suitable.
A trial whose title says "leukemia" is usually written for only one of these. ALL, CML, and CLL studies are not interchangeable with AML studies. A report that only says "leukemia" is not enough to judge eligibility.
AML starts in the bone marrow, when myeloid cells grow out of control and crowd out healthy blood cells. Two people with AML can have different gene changes, a different disease setting (newly diagnosed versus relapsed or refractory), and a different fitness for intensive treatment. Those details usually decide which treatments are standard and which clinical trials may fit.
Genetic testing looks for changes such as FLT3 (including ITD and TKD), IDH1, IDH2, and NPM1. Some of these have approved targeted drugs in defined settings — FLT3 inhibitors such as midostaurin and gilteritinib, and IDH inhibitors such as ivosidenib (IDH1) and enasidenib (IDH2). Testing at diagnosis and again at relapse decides which targeted trials may fit. Ask for the mutation results by name.